Monday, March 17, 2025 | 01:14 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Multiple growth levers make Cadila Healthcare attractive on the Street

HCQ supplies for Covid-19 treatment to propel US growth, even as domestic pharma and consumer businesses are in a sweet spot

Cadila Healthcare
Premium

Analysts feel that the street is not assigning much value for wellness business in Cadila Healthcare's overall valuations

Ujjval Jauhari
Shares of Cadila Healthcare, which had seen a lacklustre trend for almost a year before the revival a fortnight back, have surged more than 28 per cent in two days.
 
The stock scaled its 52-week high of Rs 366.55 in intra-day trade on Wednesday, before closing at Rs 350. Street sentiment has improved of late, given that the company is expected to benefit from hydroxychloroquine (HCQ) supplies to the US.

A company spokesperson said monthly HCQ production had already been ramped up from 3 tonnes to 20-30 tonnes (more than 100 million tablets) to meet requirements. In addition, Cadila will scale

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in